511 related articles for article (PubMed ID: 27943565)
1. Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: A retrospective population-based cohort study.
Driessen JH; van den Bergh JP; van Onzenoort HA; Henry RM; Leufkens HG; de Vries F
Diabetes Obes Metab; 2017 Mar; 19(3):421-428. PubMed ID: 27943565
[TBL] [Abstract][Full Text] [Related]
2. Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture.
Driessen JH; van Onzenoort HA; Henry RM; Lalmohamed A; van den Bergh JP; Neef C; Leufkens HG; de Vries F
Bone; 2014 Nov; 68():124-30. PubMed ID: 25093264
[TBL] [Abstract][Full Text] [Related]
3. Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany-A retrospective analysis of real-world data.
Dombrowski S; Kostev K; Jacob L
Osteoporos Int; 2017 Aug; 28(8):2421-2428. PubMed ID: 28455750
[TBL] [Abstract][Full Text] [Related]
4. Dipeptidyl peptidase-4 inhibitor use is associated with decreased risk of fracture in patients with type 2 diabetes: a population-based cohort study.
Hou WH; Chang KC; Li CY; Ou HT
Br J Clin Pharmacol; 2018 Sep; 84(9):2029-2039. PubMed ID: 29766544
[TBL] [Abstract][Full Text] [Related]
5. The associations of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as add-on to metformin with fracture risk in patients with type 2 diabetes mellitus.
van Hulten V; Driessen JHM; Starup-Linde JK; Al-Mashhadi ZK; Viggers R; Klungel OH; Souverein PC; Vestergaard P; Stehouwer CDA; van den Bergh JP
Diabetes Obes Metab; 2023 Nov; 25(11):3235-3247. PubMed ID: 37503747
[TBL] [Abstract][Full Text] [Related]
6. Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study.
Knapen LM; de Jong RG; Driessen JH; Keulemans YC; van Erp NP; De Bruin ML; Leufkens HG; Croes S; de Vries F
Diabetes Obes Metab; 2017 Mar; 19(3):401-411. PubMed ID: 27883260
[TBL] [Abstract][Full Text] [Related]
7. The risk of fragility fractures in new users of dipeptidyl peptidase-4 inhibitors compared to sulfonylureas and other anti-diabetic drugs: A cohort study.
Gamble JM; Donnan JR; Chibrikov E; Twells LK; Midodzi WK; Majumdar SR
Diabetes Res Clin Pract; 2018 Feb; 136():159-167. PubMed ID: 29258886
[TBL] [Abstract][Full Text] [Related]
8. Bone fracture risk is not associated with the use of glucagon-like peptide-1 receptor agonists: a population-based cohort analysis.
Driessen JH; Henry RM; van Onzenoort HA; Lalmohamed A; Burden AM; Prieto-Alhambra D; Neef C; Leufkens HG; de Vries F
Calcif Tissue Int; 2015 Aug; 97(2):104-12. PubMed ID: 25894068
[TBL] [Abstract][Full Text] [Related]
9. Effect of Dipeptidyl Peptidase-4 Inhibitors on the Risk of Bone Fractures in a Korean Population.
Ustulin M; Park SY; Choi H; Chon S; Woo JT; Rhee SY
J Korean Med Sci; 2019 Sep; 34(35):e224. PubMed ID: 31496139
[TBL] [Abstract][Full Text] [Related]
10. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
[TBL] [Abstract][Full Text] [Related]
11. Use of Dipeptidyl-Peptidase-4 Inhibitors and the Risk of Pneumonia: A Population-Based Cohort Study.
Wvan der Zanden R; de Vries F; Lalmohamed A; Driessen JH; de Boer A; Rohde G; Neef C; den Heijer C
PLoS One; 2015; 10(10):e0139367. PubMed ID: 26468883
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular outcomes of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes on insulin therapy.
Yen FS; Chiang JH; Pan CW; Lin BJ; Wei JC; Hsu CC
Diabetes Res Clin Pract; 2018 Jun; 140():279-287. PubMed ID: 29654814
[TBL] [Abstract][Full Text] [Related]
13. Use of dipeptidyl peptidase 4 inhibitors and fracture risk compared to use of other anti-hyperglycemic drugs.
Driessen JH; van Onzenoort HA; Starup-Linde J; Henry R; Neef C; van den Bergh J; Vestergaard P; de Vries F; Burden AM
Pharmacoepidemiol Drug Saf; 2015 Oct; 24(10):1017-25. PubMed ID: 26183226
[TBL] [Abstract][Full Text] [Related]
14. The risk of major osteoporotic fractures with GLP-1 receptor agonists when compared to DPP-4 inhibitors: A Danish nationwide cohort study.
Al-Mashhadi ZK; Viggers R; Fuglsang-Nielsen R; Vestergaard P; Gregersen S; Starup-Linde J
Front Endocrinol (Lausanne); 2022; 13():882998. PubMed ID: 36299454
[TBL] [Abstract][Full Text] [Related]
15. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
Mamza J; Mehta R; Donnelly R; Idris I
Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
[TBL] [Abstract][Full Text] [Related]
16. Dipeptidyl peptidase-4 inhibitors and the risks of autoimmune diseases in type 2 diabetes mellitus patients in Taiwan: a nationwide population-based cohort study.
Chen YC; Chen TH; Sun CC; Chen JY; Chang SS; Yeung L; Tsai YW
Acta Diabetol; 2020 Oct; 57(10):1181-1192. PubMed ID: 32318876
[TBL] [Abstract][Full Text] [Related]
17. Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial.
Josse RG; Majumdar SR; Zheng Y; Adler A; Bethel MA; Buse JB; Green JB; Kaufman KD; Rodbard HW; Tankova T; Westerhout CM; Peterson ED; Holman RR; Armstrong PW;
Diabetes Obes Metab; 2017 Jan; 19(1):78-86. PubMed ID: 27607571
[TBL] [Abstract][Full Text] [Related]
18. Use of incretin agents and risk of pancreatic cancer: a population-based cohort study.
Knapen LM; van Dalem J; Keulemans YC; van Erp NP; Bazelier MT; De Bruin ML; Leufkens HG; Croes S; Neef C; de Vries F; Driessen JH
Diabetes Obes Metab; 2016 Mar; 18(3):258-65. PubMed ID: 26537555
[TBL] [Abstract][Full Text] [Related]
19. Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records.
Zghebi SS; Steinke DT; Rutter MK; Emsley RA; Ashcroft DM
Diabetes Obes Metab; 2016 Sep; 18(9):916-24. PubMed ID: 27177784
[TBL] [Abstract][Full Text] [Related]
20. The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials.
Yang J; Huang C; Wu S; Xu Y; Cai T; Chai S; Yang Z; Sun F; Zhan S
PLoS One; 2017; 12(12):e0187537. PubMed ID: 29206832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
